Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial.

Journal for Immunotherapy of Cancer
Yoland AntillAustralia New Zealand Gynaecological Oncology Group (ANZGOG)

Abstract

In this study, we assessed the activity of durvalumab, an antibody to programmed death ligand-1, in two cohorts of women with advanced endometrial cancers (AEC)-mismatch repair proficient (pMMR) and mismatch repair deficient (dMMR). A multicenter phase two study was performed in women with AEC with pMMR tumor progressing after one to three lines of chemotherapy and women with AEC with dMMR tumor progressing after zero to three lines of chemotherapy. Mismatch repair status was based on immunohistochemistry expression. All women received durvalumab 1500 mg given every 4 weeks until progression or unacceptable toxicity. The primary endpoint was objective tumor response by RECIST V.1.1 modified for immune-based therapeutics. Seventy-one women were recruited: 35 dMMR and 36 pMMR. Median follow-up was 19 vs 21 months in dMMR versus pMMR, respectively. Median age was 67 years. Histology in dMMR versus pMMR included endometrioid (94% vs 57%) and serous (0% vs 31%) and was high grade in 26% vs 74%. The objective tumor response rate (OTRR) in the dMMR cohort was 47% (17/36, 95% CI 32 to 63), including 6 complete responses and 11 partial responses (PRs)) vs 3% in the pMMR cohort (1/35, 95% CI 1 to 15, PR). In the dMMR cohort, durvalumab w...Continue Reading

References

Feb 1, 1983·Gynecologic Oncology·J V Bokhman
May 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Franco M MuggiaGary C Reid
May 31, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Scott WadlerGary Goldberg
Jul 8, 2008·Gastroenterology·Leigha SenterAlbert de la Chapelle
Dec 24, 2009·Journal of the National Cancer Institute·Laura BagliettoMark A Jenkins
Dec 15, 2010·The Lancet Oncology·Marlies J E KempersMarjolijn J L Ligtenberg
Jan 13, 2012·Current Opinion in Immunology·Suzanne L TopalianDrew M Pardoll
Dec 21, 2012·Human Mutation·James G DowtyMark A Jenkins
May 3, 2013·Nature·Cyriac KandothDouglas A Levine
Sep 28, 2013·Nature Genetics·UNKNOWN Cancer Genome Atlas Research NetworkJoshua M Stuart
Apr 11, 2015·Cancer Cell·Suzanne L TopalianDrew M Pardoll
Jun 2, 2015·The New England Journal of Medicine·Dung T LeLuis A Diaz
May 10, 2016·The Journal of Clinical Investigation·Janice M MehnertShridar Ganesan
Jul 15, 2016·The Oncologist·Valerie LeeLuis A Diaz
Mar 9, 2017·The Lancet Oncology·Lesley SeymourUNKNOWN RECIST working group
May 11, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patrick A OttJean-Charles Soria
Feb 14, 2018·Journal of the National Comprehensive Cancer Network : JNCCN·Wui-Jin KohJillian L Scavone
Feb 28, 2018·Journal of Hematology & Oncology·Xiaolei LiWeidong Han
Mar 14, 2018·Journal of Gynecologic Oncology·Christina M NagleUNKNOWN Australian Endometrial Cancer Study Group
Aug 29, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Panagiotis A KonstantinopoulosUrsula A Matulonis
Nov 5, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Aurelien MarabelleLuis A Diaz
Aug 5, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alicia León-CastilloUNKNOWN TransPORTEC consortium

❮ Previous
Next ❯

Software Mentioned

iRECIST
RECIST

Related Concepts

Related Feeds

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.